Status:
RECRUITING
Reducing High Risk Primary Tumor Clinical Target Volumes (CTVp1) in Non-metastatic Nasopharyngeal Carcinoma
Lead Sponsor:
Zhongshan People's Hospital, Guangdong, China
Collaborating Sponsors:
Sun Yat-sen University Cancer Centre
Conditions:
Nasopharyngeal Carcinoma
Intensity-Modulated Radiotherapy
Eligibility:
All Genders
18-70 years
Phase:
NA
Brief Summary
To evaluate the long-term local control, survival rate, acute and late radiation related toxicities, quality of life after reducing high risk primary tumor clinical target volumes (CTVp1) in non-metas...
Detailed Description
This phase 3, multicenter,randomized controlled clinical trial recruits patients with newly-diagnosed non-metastatic nasopharyngeal carcinoma patients treated with IMRT. The intervention is delineatin...
Eligibility Criteria
Inclusion
- histologic confirmation of nonkeratinizing nasopharyngeal carcinoma(WHO II-III);
- newly diagnosed stage I to IVa according to the American Joint Committee on Cancer-Union for International Cancer Control 8th edition stage-classification system
- nasopharyngeal mass confined to one side of nasopharynx and did not exceed the midline(the line between the nasal septum and the midpoint of spinal cord/medulla) detected by electronic nasopharyngoscope (ENS) and magnetic resonance imaging (MRI). Pathological biopsy was recommended if it was unclear whether tumor invaded the contralateral side radiographically.
- planned to receive curative IMRT, Chemotherapy drugs should be administered according to Chinese Society of Clinical Oncology (CSCO) guidelines depending on the TNM stage;(T1N0: No chemotherapy required;T2N0：No chemotherapy or concurrent cisplatin chemoradiotherapy if there are adverse prognostic indicators such as Epstein-Barr virus (EBV) DNA\>4000 copies，node \>3cm or with extranodal extension;T1-2N1: concurrent cisplatin chemoradiotherapy;T3N0: concurrent cisplatin chemoradiotherapy; stage III-Iva: platinum-based neoadjuvant chemotherapy+ concurrent cisplatin chemoradiotherapy+/-metronomic capecitabine therapy )
- no previous treatment for cancer；
- a Karnofsky performance-status score of at least 70 (on a scale from 0 to 100, with lower scores indicating greater disability);
- between 18 and 70 years old;
- adequate hematologic, renal, and hepatic function: Adequate marrow function: WBC count ≥ 3×10E9/L, NE count ≥ 1.5×10E9/L, HGB ≥ 90g/L, PLT count ≥ 100×10E9/L;Adequate liver function: ALT and AST ≤ 2.5×ULN, TBIL ≤ 2.0×ULN;Adequate renal function: BUN and CRE ≤ 1.5×ULN , endogenous creatinine clearance ≥ 60ml/min (Cockcroft-Gault formula);
- Patients must be informed of the investigational nature of this study and give written informed consent.
Exclusion
- receipt of treatment with palliative intent;
- receipt of previous treatment (radiotherapy, chemotherapy, or surgery \[except diagnostic procedures\]) to the nasopharynx;
- had disease progress after neoadjuvant chemotherapy in local advantage NPC
- presence of distant metastasis;
- Keratinized squamous cell carcinoma or basal cell like squamous cell carcinoma;
- Prior malignancy except adequately treated non-melanoma skin cancer, in situ cervical cancer, and papillary thyroid carcinoma;
- Have New York Heart Association (NYHA) class 3 or 4, unstable angina, myocardial -infarction within 1 year, or clinically meaningful arrhythmia that requires treatment;
- lactation or pregnancy;
- Any other condition including Mental disorder,drug or alcohol addition;do not have full capacity for civil acts.
Key Trial Info
Start Date :
August 4 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2029
Estimated Enrollment :
454 Patients enrolled
Trial Details
Trial ID
NCT05994170
Start Date
August 4 2023
End Date
September 1 2029
Last Update
August 16 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zhongshan City People's Hospital
Zhongshan, Guangdong, China, 528403